Hamza Suria, former AnaptysBio CEO
March 22, 2022 07:19 AM EDT
People

Anap­tys­Bio CEO abrupt­ly re­signs less than a week af­ter mid-stage flop

Max Gelman

Senior Editor

Less than a week af­ter Anap­tys­Bio dropped an­oth­er in­di­ca­tion for its lead drug, the biotech’s long­time CEO has de­cid­ed to tap out.

Hamza Suria ten­dered …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times